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We and others have previously described signatures of
tolerance in kidney transplantation showing the differ-
ential expression of B cell–related genes and the relative
expansions of B cell subsets. However, in all of these
studies, the index group—namely, the tolerant recipi-
ents—were not receiving immunosuppression (IS)
treatment, unlike the rest of the comparator groups.
We aimed to assess the confounding effect of these reg-
imens and develop a novel IS-independent signature of
tolerance. Analyzing gene expression in three indepen-
dent kidney transplant patient cohorts (232 recipients
and 14 tolerant patients), we have established that the
expression of the previously reported signature was
biased by IS regimens, which also influenced transi-
tional B cells. We have defined and validated a new
gene expression signature that is independent of drug
effects and also differentiates tolerant patients from
healthy controls (cross-validated area under the recei-
ver operating characteristic curve [AUC] = 0.81). In a
prospective cohort, we have demonstrated that the
new signature remained stable before and after steroid
withdrawal. In addition, we report on a validated and
highly accurate gene expression signature that can be
reliably used to identify patients suitable for IS reduc-
tion (approximately 12% of stable patients), irrespective
of the IS drugs they are receiving. Only a similar
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approach will make the conduct of pilot clinical trials
for IS minimization safe and hence allow critical
improvements in kidney posttransplant management.
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Introduction
Despite improvements in the stratification of therapy in
kidney transplant recipients (KTRs), grafts do not display
the desired longevity. The immunosuppression (IS) needs
of individual patients are poorly defined, and the current
approaches are far from an ideal personalized manage-
ment program. Standard KTRs are maintained with
calcineurin inhibitors (CNIs) or sirolimus on doses defined
by blood levels and azathioprine (Aza) is adjusted on
weight, whereas mycophenolate mofetil (MMF) or
prednisone doses are given as population-based results
dictate (1,2). As a result, overimmunosuppression is
responsible for a high number of patients with a function-
ing graft dying or suffering from cancer, infections or
cardiovascular events (3). For example, prolonged intake
of azathioprine has long been associated with increased
incidence of tumors, particularly skin cancers in KTRs (4).
At the same time, underimmunosuppression remains a
clinical problem in that acute rejection is still frequent (5),
albeit decreasing in magnitude, and chronic rejection is
definitively significant and has a poor outcome (6). This
means that there is an important clinical need to charac-
terize biomarker signatures that could reliably identify
patients who have developed a tolerant response to their
graft. We and others have been trying to address this
need (7–11).
The index patient group that is central to identifying toler-
ance is formed by those kidney transplant recipients
(KTRs) who have challenged conventional clinical practice
and have discontinued immunosuppressive medication
while maintaining good graft function for years (12);
these recipients are thus labeled as “tolerant.” In the
process of biomarker discovery, these tolerant KTRs—
free from IS for years—have always been compared with
KTRs receiving various IS regimens, who are representa-
tives of nontolerant patients. These differences in ther-
apy between the groups imply that any previous
signatures suffer from a systematic analysis flaw if the
effects of the drugs have not been accounted for.
The final proof that any biomarker signature is indeed a
signature of tolerance would only arise through a clinical
trial whereby patients displaying the chosen signature
would be weaned off IS and their graft would maintain
good function. This definitive evidence for any signature
tolerance is still missing in the literature. Consequently,
the selection of possible signatures of tolerance need to
abide by the most stringent quality requirements because
testing them in prospective trials would put some patients
at risk of late rejection or even at risk of irreversible graft
damage if a misdiagnosis is made. To our knowledge,
none of the referenced studies have yet attempted to
directly address the fact that IS drugs affect gene expres-
sion despite available evidence (13,14). Notably, a noninva-
sive signature of tolerance could also be used to evaluate
the effectiveness of tolerance induction therapies that are
currently under investigation in clinical trials (15–17).
Gene expression patterns found in the peripheral blood of
KTRs can reflect at least two mechanisms: the response
of the recipient’s immune system to the presence of a
highly immunogenic tissue (the transplanted graft) and the
effect of IS treatment used to counteract the rejection pro-
cess. Edemir et al (18) used a rodent model to describe
gene expression patterns that support the spontaneous
simultaneous activation of immune effector–related path-
ways and protective and immune counter-regulatory
mechanisms as a response to the allogeneic transplant. In
humans, we and others have previously described a dys-
regulation of B cell–related genes in tolerant recipients—
associated with the maintenance or expansion of transi-
tional B cells in peripheral blood (8,9)—that elicited new
avenues toward understanding the role of transitional B
cells in tolerance (19–21). Differential expression profiles
associated with IS treatment have been demonstrated by
Erickson et al (22) in the context of transplantation in rats.
Thus, when investigating gene expression markers of
operational tolerance in humans, we need to ensure that
we are isolating the natural counter-regulatory immune
mechanisms from those that reflect the IS drug intake,
which could disappear after discontinuation of the drug.
We therefore undertook the current study to explore the
effects of IS regimens on gene expression in peripheral
blood and on our previously described signature of tolerance
Sagoo et al (8) and hypothesized that adjusting for the con-
founding effects of IS drugs would provide more reliable
biomarkers. We also hypothesized that by targeting
immune responses via different mechanisms, IS drugs
would have a differential effect on lymphocyte populations,
particularly that of transitional B cells, which could bias the
probability of tolerance estimates if differences in IS drug
regimens are not accounted for. As a proof of concept of
the effect of IS on lymphocyte subsets and gene expres-
sion, we have prospectively collected samples from
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patients who underwent steroid withdrawal owing to clini-
cal reasons.
Concise Materials and Methods
Patients and samples
To collect the necessary evidence described in this article, we used sam-
ples from three patient cohorts:
 Cohort 1: We performed a reanalysis of the data from 71 European
KTRs from the previously published Indices of Tolerance (IoT) study.
This patient cohort had been used to discover the original biomarker
signature and comprised 11 tolerant recipients, 51 stable patients (30
on standard triple therapy, 10 who had never received a CNI and 11
on low doses of prednisone), 9 patients with biopsy-proven chronic
rejection and 19 healthy controls; these patients are all thoroughly
described in reference (8).
 Cohort 2: Cohort 2 is a novel observational case-control cohort from
the Genetic Analysis of Molecular Biomarkers of Immunological Toler-
ance (GAMBIT) study (Research Ethics Reference: 09/H0713/12). The
cohort comprised tolerant (n = 14; detailed description in Table S3),
stable (n = 190) and chronic rejection (n = 36) patients and healthy
controls (n = 12). At least two blood samples—6 months apart on
average—were obtained from each individual; these are identified in
the text as time point 1 and time point 2.
 Cohort 3: Cohort 3 is a prospective cohort from the same GAMBIT
study (Research Ethics Reference: 09/H0713/12) that included stable
patients who, early posttransplant, were undergoing steroid withdrawal
owing to clinical reasons. These patients were selected exclusively
based on clinical criteria and were recruited from the London and
Portsmouth hospitals. Patient selection and steroid withdrawal were
conducted according to local clinical practice. Samples were collected
before and 2 to 6 months after complete steroid withdrawal.
Patient characteristics from cohorts 2 and 3 are described in Table 1, and
further clinical details are given in Data S1.
The characteristics of the patients in the prospective steroid withdrawal
cohort 3 were largely comparable to the observational cohort 2 (Table 1),
except that their time posttransplantation was significantly shorter
(p < 0.001), none had Donor Specific Antibodies (DSA) and none were
receiving azathioprine, whereas all but one were treated with mycophe-
nolate mofetil (Table 1).
RNA isolation, complementary DNA (cDNA) synthesis and
reverse transcription quantitative real-time polymerase chain
reaction (RT-qPCR)
Peripheral vein blood was drawn directly into Tempus Blood RNA Tubes
(Life Technologies, Paisley, UK) and stored at 20°C. RNA isolation,
cDNA synthesis, RT-qPCR conditions and primers are described in Data
S1.
Fluidigm platform
The expression levels of a set of target genes and three endogenous ref-
erence genes were measured in 470 RNA samples on the Fluidigm Bio-
Mark quantitative real-time PCR (qPCR) platform (South San Francisco,
CA) with a preamplification step to validate the signature rederived from
the IoT cohort. Further details are given in Data S1.
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated and frozen
immediately at 80°C. After 24 h, cells were transferred into liquid
nitrogen 170°C and kept until use. Antibody panels and acquisition
details are described in Data S1.
Statistical analyses
The analysis strategy is depicted in Figure 1. All statistical analyses (pre-
processing of RT-qPCR, Fluidigm and array data) were carried out in R
software (http://www. R-project. org/) (23–25). For individual gene expres-
sion, Ct values were normalized using DCt with respect to HPRT (hypox-
anthine phosphoribosyltransferase) and were used as log2(2DCt) values.
Associations of gene expression or of predicted probability of tolerance
with IS drug intake were examined in linear regression models adjusting
simultaneously for confounding by IS drugs other than the drug of inter-
est. Bonferroni correction was applied for multiple comparisons between
patients on and off different drugs.
Elucidating the confounding effect of IS on gene expression
Details of the RISET 2.0 array and the preprocessing method have been
published elsewhere (8). The array-wide analysis of drug effects was car-
ried out using empirical Bayes moderated linear models implemented in
the Limma package (26). The Benjamini–Hochberg (BH) method was
used for multiple testing correction. Genes for which expression was not
significantly above background were filtered out prior to analysis to
increase statistical power (27).
Defining IS-independent expression
The residuals of a linear regression model relating gene expression data
from stable and chronic rejector patients to drug intake (binary yes/no)
represent the IS-independent expression (IS-IE). The gene expression of
tolerant patients and healthy controls was rescaled to IS-IE by subtracting
the intercept of that model from the raw expression.
Defining the novel signature of tolerance
We used the regularized multivariate logistic regression method ElasticNet
(28,29) to select an optimal set of genes predictive of tolerance (as the
number of genes was high relative to the number of patients), and consid-
ering many genes were correlated, thus invalidating the application of clas-
sical regression models. We compared the estimated IS-IE in tolerant
patients versus patients on IS (stable and with chronic rejection). In order
to test the stability of the signatures, IS-IE from the time point 2 samples
was estimated based on the model trained on time point 1 samples, and
classification accuracy was evaluated with the same cutoff.
For the identification of differentially expressed biological pathways, we
carried out gene set analysis (30) using the curated list of gene sets from
the Broad Institute (www. broadinstitute.org/gsea).
For the evaluation of predictive accuracy, an adjusted area under the recei-
ver operating characteristic curve (AUC) was derived after fitting a linear
regression model of the estimated probability of tolerance on drug regimen
in IS patients and calculating the AUC for the residuals of this model (31).
Further details regarding the laboratory methods and statistical analysis
are provided in Data S1.
Results
Immunosuppressants bias the expression of genes in
peripheral blood
To study the effects of commonly used immunosuppres-
sants on the expression of genes measured in peripheral
blood, we first carried out a previously unattempted
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1. Confounding effect of IS on the expression of genes
RT-qPCR analysis 
of IoT signature 
GAMBIT patients 
(Cohort 2, time point 1)
Array-wide Empirical Bayes moderated 
linear models analysis 
LIMMA [26] + FDR a
IoT patients (Cohort 1)
IoT custom array RISET2.0 Agilent 
(5069 probes, 4607 genes)
Gene Set    
Analysis
GSA [30] c
Flow cytometry
GAMBIT patients (Cohort 2)
Multiple Linear Regression residual estimates b
IoT patients (Cohort 1)
RISET2.0 array gene expression
(1989 probes post QC)
Feature selection using IS-IE 
Regularized Multivariate 
Logistic Regression 
Elastic Net 
GLMNET [25] d
(28-gene selection)
Multiple Linear Regression 
residual estimates (IS-IE)
GAMBIT patients (Cohort 2)
Fluidigm RT-qPCR
(26 validated array-selection genes)
Feature selection using IS-IE 
Regularized Multivariate Logistic 
Regression – Elastic Net 
GLMNET [25] e
(9-gene signature)
GAMBIT patients (Cohort 2, time point 1)
2.  Effects of Drugs on Lymphocyte subset distribution
3.  Immunosuppression-Independent Expression (IS-IE)
Validation
Validation
Proof of 
Concept
RT-qPCR analysis 
of IoT signature 
GAMBIT patients 
(Cohort 3)
Proof of Concept Flow cytometry
GAMBIT patients (Cohort 3)
Evaluation of Signature Stability
(9-gene signature)
GAMBIT patients (Cohort 2, time point 2)
Proof of 
Concept
Fluidigm
RT-qPCR
GAMBIT patients 
(Cohort 3)
Figure 1: Analysis strategy to demonstrate confounding effect of IS and how to avoid it. A complete description can be found
in Data S1. In summary: aProbes with nonsignificant expression above background in more than 20% of the samples were filtered
out. The effects of three factors were estimated: CNI: (ciclosporin [Cyc], tacrolimus [Tac], none), MMF/Aza (mycophenolate mofetil,
azathioprine, none) and prednisone-Pred-(Pred; on steroids, off steroids). bThe model for the ith patient and the jth Gene Set Analysis
gene was yij = aj + Cyci *bCycj + Taci *bTacj + Azai *bAzaj + MMFi *bMMFj + Predi *bPredj + eij. This was estimated using data from stable
and chronic rejector patients. The resulting estimated residual eij represents the IS-independent gene expression (IS-IE). The gene
expression of tolerant patients and healthy controls was rescaled to IS-IE by subtracting the intercept aj from the raw expression.
cGSA was used for the identification of differentially expressed biological pathways based on the curated list of gene sets from the
Broad Institute (www.broadinstitute.org/gsea). Gene sets with an associated FDR below 10% were considered differentially
expressed. dIn ElasticNet regression, a penalty is imposed on the regression coefficients, which is a combination of the penalties used
in lasso and ridge regression. ElasticNet enables selection of genes (unlike ridge regression, which would preserve all genes) as well
as gene groups irrespective of correlation (unlike lasso, which would select only one of a group of correlated genes). Model parame-
ters were tuned using leave-group-out cross-validation with a 65% training set and 100 resampling iterations, with the AUC as an
accuracy measure, via the caret package in R (29). Prior to model estimation, missing values were imputed using K-nearest neighbors.
Genes for which the expression was not significantly above background (p > 0.01) in at least 80% of the samples were filtered out
prior to analysis (3081 out of 5070 probes) to increase statistical power (10). eClassification cutoffs were selected to ensure specificity
above 0.85 while retaining sensitivity above 0.70. IS, immunosuppression; CNI, calcineurin inhibitors; Aza, azathioprine; MMF,
mycophenolate mofetil; IS-IE, IS-independent expression; GLMNET, Lasso and Elastic-Net Regularized Generalized Linear Models;
GSA, Gene Set Analysis; FDR, false discovery rate; AUC, area under the receiver operating characteristic curve; GAMBIT, Genetic
Analysis and Monitoring of Biomarkers of Immunological Tolerance; IoT, Indices of Tolerance; RT-qPCR, reverse transcription quantita-
tive real-time polymerase chain reaction; RISET, Reprogramming the Immune System for the Establishment of Tolerance.
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array-wide analysis of drug effects using the expression
measured on the original data from the IoT study (8).
This revealed that 119 genes were differentially
expressed in association with CNI drug intake and that
83 genes were associated with MMF and azathioprine
intake, whereas only one gene was exclusively affected
by steroid intake (Table S1).
To confirm the effect of IS, we then assessed the effect
of IS on the expression of the previously published 10
genes of the signature using samples from stable
patients on IS from cohort 2 (time point 1) of the GAM-
BIT study (8). A summary of the different IS regimens
the patients were under is provided in Table S2. Pred-
nisone and azathioprine showed statistically significant
effects on the expression of 7 out of 10 of the previously
described individual genetic markers of tolerance
(Table 2). The effects of each drug were adjusted for the
intake of other IS drugs.
To measure the magnitude of these effects, we calcu-
lated the percentage of variance in the expression of
each gene explained by drug effects (R2 values from lin-
ear regression models based on data from the GAMBIT
cohorts 2 and 3; Table S4). For 5 genes among the 10 in
the original IoT signature, the percentage of expression
explained by drugs was at or higher than 10% and up to
27% (CD79b, TCL1A, SH2DB1, FCRL1, and MS4A1), fur-
ther strengthening the argument that the expression of
genes included in the IoT signature was influenced by IS
drug regimens.
We then calculated the probability of tolerance for each
patient based on the RT-qPCR expression in peripheral
blood samples. We used the gene expression from the
previously published IoT signature, as described (8) for
patients from cohort 2, time point 1, of the GAMBIT
study. We observed that this probability was undeniably
and significantly associated with the drug exposure of
the patients (Figure 2). The probability was significantly
lower in stable patients treated with azathioprine com-
pared to patients off antiproliferative (p < 0.0001) and
patients on MMF (p < 0.0001) (Figure 2A). This probabil-
ity was not influenced by the intake of CNIs once the
effects of prednisone and azathioprine were accounted
for (Figure 2B). Similar to azathioprine, the administration
of prednisone was associated with a significantly lower
estimated probability of tolerance (p < 0.0001) in stable
patients in GAMBIT cohort 2 (Figure 2C; note that the
patients shown in this plot are all off azathioprine).
To further confirm this observation, we used the gene
expression from samples in the prospective GAMBIT
cohort 3 (p = 0.008). Indeed, the estimated probability of
tolerance significantly increased after steroid withdrawal
(Figure 2D; please note that no patient in this group was
receiving azathioprine).
The AUC for the probability of tolerance estimates from
the comparison between tolerant and IS-treated patients
from GAMBIT cohort 2, based on the IoT signature, was
0.89 (95% confidence interval [CI]: 0.83–0.94). When the
AUC was adjusted for the effects of IS drugs, it became
significantly lower: 0.77 (95% CI 0.67–0.86; p = 0.032).
This provided further evidence for a confounding effect
of IS regimens in the expression of these genes.
Therefore, we have demonstrated, in three completely
independent cohorts (1, 2 and 3), evidence of drug con-
founding or bias in the gene expression of our previously
identified tolerance signature.
Immunosuppressants affect the transitional B cell
subset
Whole blood gene expression data are greatly influenced
by the repertoire of circulating lymphocyte subsets. To
Table 2: Effects of IS drugs on the published signature in stable patients from the GAMBIT study
Gene Symbols Pred Cyc Tac Aza MMF
PNOC 0.11 0.10 0.04 0.76 1.00
CD79b 2.1 9 1004 1.00 0.12 8.1 9 1004 0.94
TCL1A 1.9 9 1006 0.17 0.02 6.7 9 1016 1.00
H3ST1 1.3 9 1004 0.30 0.14 3.6 9 1005 0.20
SH2DB1 0.42 1.00 1.00 <2.0 9 1016 0.11
TLR5 4.0 9 1003 1.00 0.09 1.00 1.00
MS4A1 3.0 9 1003 0.73 0.18 1.1 9 1004 1.00
FCRL1 1.7 9 1004 1.00 0.73 1.1 9 1010 1.00
FCRL2 5.7 9 1004 1.00 0.15 1.6 9 1005 1.00
FoxP3/AMann 0.69 0.16 9.0 9 1003 1.00 1.00
p-values for comparisons of stable patients on and off each drug are derived after adjustment in a linear regression model for all other
drugs/drug groups. The p-values for the Cyc/Tac group (subgroups No-Cyc/Tac, Cyc, and Tac) and for the Aza/MMF group (subgroups
No-Aza/MMF, Aza, and MMF) were adjusted for multiple comparisons with Bonferroni correction.
Aza, azathioprine oral dose; Cyc, cyclosporine A trough levels; GAMBIT, Genetic Analysis of Molecular Biomarkers of Immunological
Tolerance; IS, immunosuppression; MMF, mycophenolate mofetil oral dose; Pred, prednisone oral dose; Tac, tacrolimus trough levels.
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determine whether the previously described association
of tolerance with a relative increase in circulating transi-
tional B cells in tolerant recipients might also be con-
founded by IS, we performed flow cytometry analysis of
peripheral blood cells from the patients included in GAM-
BIT cohort 2 (for gating, see Figure S2). The effect of IS
drugs was clearly evident in the percentage of transi-
tional B cells within the naive B cell population (Figure 3),
and this effect was similarly observed when measuring
absolute numbers of cells in a subset of the recipients
(Figure S3). Notably, the pattern of the changes closely
resembled the effect of IS drugs on the estimated proba-
bility of tolerance based on the IoT signature. Stable
patients on azathioprine (Figure 3A) and those on pred-
nisone (Figure 3C) showed lower percentages of transi-
tional B cells than patients off each of these drugs,
whereas CNI drugs showed no effect (Figure 3B). The
effect of prednisone showed a clear dose–response rela-
tionship (Figure 3D), and this was confirmed in the
prospective steroid withdrawal GAMBIT cohort 3
Figure 2: Effects of immunosuppression (IS) drugs on the estimated probability of tolerance based on the 10-gene algorithm
from IoT (gene expression measured by RT-qPCR in patients from the GAMBIT study, cohorts 2 and 3). (A) Effect of antiprolif-
erative drug intake in the stable patients group (n = 171) (No-MMF/Aza patients not receiving MMF nor Aza n = 31), Aza n = 61,
MMF n = 79. (B) Effect of CNI drug intake in the stable patients group (n = 171) (No-Cyc/Tac patients not receiving Cyc nor Tac
n = 40, Cyc n = 82, Tac n = 49). (C) Effect of prednisone intake on the estimated probability of tolerance in stable patients off azathio-
prine (n = 110) (Pred n = 48, No-Pred n = 62). (D) Comparison of paired samples prewithdrawal and 3 to 6 months postwithdrawal
completion from patients who have undergone clinically driven steroid withdrawal (n = 13 due to missing samples, none receiving aza-
thioprine). The p-values for each drug were derived after adjustment in a linear regression model for effects of all other drugs. The
p-values for CNI drugs and for antiproliferative drugs were adjusted for multiple comparisons with Bonferroni correction. The p-values
for comparisons pre– and post–steroid withdrawal were derived from a Wilcoxon matched pairs test. Cyc, ciclosporin; Tac, tacrolimus;
Pred, prednisone/prednisolone; Aza, azathioprine; IS, immunosuppression; IoT, Indices of Tolerance study; RT-qPCR, reverse transcrip-
tion quantitative real-time polymerase chain reaction; GAMBIT, Genetic Analysis of Molecular Biomarkers of Immunological Tolerance;
MMF, Mycophenolate mofetil. Probability of tolerance cutoff was 0.62.
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(Figure 3E). The percentage of total B cells in periphery
significantly decreased only for those patients taking aza-
thioprine (data not shown). Changes in the opposite
direction were observed in the percentages of T cells
from lymphocytes. These were increased in stable
patients taking azathioprine or prednisone but were unaf-
fected by CNI drugs (Figures S1A, B and D). However,
the evidence for a dose–response effect of prednisone
was very weak, and there were no differences in the
percentages of peripheral blood T cells in the prospective
steroid withdrawal cohort 3 (Figures S1E and F).
Development of a novel immunosuppression-
independent gene expression signature of tolerance
Having demonstrated that the IS drug regimen is a con-
founder for the association between gene expression
levels and the predicted probability of tolerance, we
concluded that for a predictive test of tolerance to be
clinically applicable and unbiased, IS effects on gene
expression must be accounted for in the predictive
algorithm. We used the array data from the IoT study
(cohort 1) as a “discovery” set. We obtained the resi-
duals of a multivariate linear regression model for IS
drugs per each gene in the array. We used this to
estimate the IS-independent gene expression (IS-IE)
per gene.
We used the estimated IS-IE to select an optimal set of
genes predictive of tolerance. To enable applicability of
the signature in a clinical setting, we restricted the selec-
tion to a maximum of 30 genes. The resulting set of 28
IS-independent genes provided excellent predictive
Figure 3: Percentage of CD24hiCD38hi (transitional B cells) within the live CD20 + CD19 + B lymphocytes and CD27-
IgD+IgM+ gate in peripheral blood of patients from the GAMBIT study, cohorts 2 and 3. (A) Effect of antiproliferative drug intake
on transitional B cell subset size in the stable patients group (n = 111) (No-MMF/Aza n = 33, Aza n = 24, MMF n = 54). (B) Effect of
CNI drug intake (n = 111) (No-Cyc/Tac n = 28, Cyc n = 41, Tac n = 42). (C) Effect of prednisone intake on the transitional B cell subset
size in stable patients off azathioprine (n = 87) (Pred n = 53, No-Pred n = 34). (D) Effect of prednisone total daily dose (mg) in stable
patients off azathioprine. (E) Comparison of paired samples prewithdrawal and 3 to 6 months postwithdrawal completion from patients
who have undergone clinically driven steroid withdrawal (n = 16, none receiving azathioprine). The p-values for each drug are derived
after adjustment in a linear regression model for all other drugs/drug groups. The p-values for CNI drugs and for antiproliferative drugs
were adjusted for multiple comparisons with Bonferroni correction. The p-values for comparisons pre– and post–steroid withdrawal
were derived from a Wilcoxon matched pairs test. Cyc, ciclosporin; Tac, tacrolimus; Pred, prednisone/prednisolone; Aza, azathioprine;
IS, immunosuppression; IoT, Indices of Tolerance study; GAMBIT, Genetic Analysis of Molecular Biomarkers of Immunological Toler-
ance; MMF, Mycophenolate Mofetil; CNI, Calceneurin Inhibitors.
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accuracy (Figures 4A and B; AUC, sensitivity and speci-
ficity of 1; cross-validated AUC = 0.98).
Subsequently, using this IS-IE expression, gene set anal-
ysis revealed five differentially expressed biological path-
ways: nuclear factor kappa B (NFjB), CD40, tumor
necrosis factor (TNF), Granulocyte-macrophage colony-
stimulating factor (GMCSF), and Glucocorticoid receptor
regulatory network (REGGR; of which only CD40 and
NFjB could be identified as preferential gene pathways
in B cells). The resulting prediction sets also provided
excellent predictive accuracy to identify tolerant recipi-
ents (Figure 4B).
Validation of the new signature on Fluidigm
platform in samples from the GAMBIT study
We chose to validate and further refine the new IS-IE gene
set using the Fluidigm platform, an RT-qPCR–based assay,
in samples from patients in GAMBIT cohort 2 (time point
1). Quality control criteria were met by 26 genes.
A set of 9 genes out of the 26 was selected by Elas-
ticNet as optimal to predict tolerance (see Data S1).
Table 3 shows the validated IS-IE nine-gene list. Please
note that drugs explained very little of the variance of
their expression (see R2 in Table S5). No gene over-
lapped with the previous IoT signature.
The new IS-IE estimated probability of tolerance was
independent of IS regimen—and therefore unconfounded
—in stable patients (p > 0.05 for all drugs) from GAMBIT
cohort 2 (Figures 5A, B and C). Further, in the prospec-
tive GAMBIT cohort 3, we could demonstrate that ster-
oid withdrawal does not affect the expression of this
new gene signature (Figure 5D).
The predictive accuracy of the new signature, as evaluated
by the AUC, was 0.93 (95% CI: 0.86–1.0) and 0.81 after
optimism correction via cross-validation. A classification
cutoff of 0.54 was selected to maximize specificity for
patient safety (sensitivity of 0.92, specificity of 0.88).
AUC CV-
AUC
Cutoff Sens Spec
GLMNET 1.00 0.98 0.73 1.00 1.00
CD40 1.00 0.93 0.76 1.00 1.00
TNF 0.98 0.94 0.70 1.00 0.96
NF  B 1.00 0.99 0.77 1.00 1.00
GMCSF 0.96 0.95 0.75 0.90 0.98
REGGR 0.97 0.89 0.78 0.80 0.96
A
B
Figure 4: Discovery of a new set of IS-independent markers of tolerance. (A) Heat map showing patterns of residual gene
expression from 28 genes selected using ElasticNet on array data from the IoT cohort, comparing tolerant versus immunosuppressed
recipients. (B) Predictive accuracy of multivariate predictive sets of genes. GLMNET refers to the 28-gene set discovered via Elas-
ticNet analysis. The remaining sets were selected from those molecular pathways shown to be differentially expressed via gene set
analysis. AUC, area under the receiver operating characteristic curve; CV-AUC, cross-validated AUC; IoT, Indices of Tolerance; Sens,
sensitivity; Spec, specificity; GLMNET, Elastic Net Regularized General Linear Model; REGGR, Glucocorticoid receptor regulatory net-
work; TNF, Tumor Necrosis Factor Pathway; CD40, CD40L Signaling Pathway; NFKB, NF-kappaB Signaling Pathway; GMCSF, GMCSF-
mediated signaling events.
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Based on the IS-IE signature, 20 out of 173 patients from
cohort 2 on IS with stable function were identified as
“probably tolerant” (11.6%). These patients were differ-
ent individuals from those identified with the IoT signa-
ture (n = 25) (only two overlapping). Comparison of the
two groups (Tables S6 and S7; Data S1) revealed, impor-
tantly, that the IS-IE selection had significantly longer
time posttransplantation, making them more comparable
to the index group of tolerant patients.
Evaluation of the stability of the signature developed in
cohort 1 (by estimating its predictive accuracy in two
time points in cohort 2) showed satisfactory performance
(AUC time point 2 = 0.83; 95% CI: 0.67–0.99). Addition-
ally, a nonsignificant McNemar’s test indicated that bin-
ary classification is stable across repeated samples
(p = 0.095), meaning that classifications at one time
point are not significantly different from those at a subse-
quent time point. Furthermore, the continuous predicted
probability of tolerance does not change significantly
between time points (Figure S4).
The genes included in the new signature participate in
cellular pathways such as regulation of nucleic acid
metabolism (GEMINI7, NFjB1A, TNFIP3), cell communi-
cation activities (RAB40C) and transcription factor activity
(EEF1A1, NFjB1A, TNFIP3). Still, the protein expression
derived from three of the genes has been observed in B
cells and in other cells (BCL2A1, EEF1A1) or in B cells
exclusively (IGLC1; see Table 3).
The new IS-independent signature is differentially
expressed in healthy controls
An important limitation of the previously described sig-
natures is their inability to differentiate between toler-
ant recipients and healthy controls (as illustrated in
Figure 6A for the IoT signature). Similarly, we have
observed no difference in the transitional B cell per-
centages in peripheral blood between these two
groups (Figure 6B). Importantly, the predicted probabil-
ity of tolerance based on the new signature was
higher in tolerant patients compared to healthy controls
(Figure 6C). This suggests that the method proposed
herein and the resulting novel signature indeed capture
an underlying predisposition to tolerance rather than
the absence of IS drugs. Comparisons of the predicted
probabilities of tolerance in tolerant patients and
healthy controls with the corresponding cutoffs for the
Table 3: Immunosuppression-independent gene signature
Symbol Gene name Molecular function Biological processes Documented protein expression in
ATXN3 ↓ Ataxin 3 Ubiquitin-specific
protease activity
Protein metabolism Caudate nucleus, cerebellum
frontal cortex, pons,
ubiquitous
BCL2A1 ↓ BCL2-related protein A1 Receptor signaling
complex
scaffold activity
Apoptosis B cell (49), bone marrow,
colon, intestine, leucocyte,
lymph node, ovary, spleen,
T cell
EEF1A1 ↓ Eukaryotic translation
elongation factor
1 alpha 1
Transcription
regulator activity
Regulation of cell cycle B cell (50), islets of
Langerhans, lachrymal
gland, leukocyte, monocyte,
neutrophil, plasma, saliva,
semen, skeletal muscle,
tear
GEMIN7 ↑ Gem (nuclear organelle)
associated protein 7
Ribonucleoprotein Regulation of nucleobase,
nucleoside, nucleotide
and nucleic acid
metabolism
Spinal cord tissues
IGLC1 ↑ Immunoglobulin lambda
constant 1 (Mcg marker)
Antigen binding Immune response B lymphocytes (51)
MS4A4A ↑ Membrane-spanning 4-domains,
subfamily A, member 4A
– – Intestine and colon
NFjBIA ↓ Nuclear factor of kappa light
polypeptide gene enhancer in
B cells inhibitor, alpha
Transcription
regulator activity
Regulation of nucleobase,
nucleoside, nucleotide
and nucleic acid
metabolism
Neutrophil, T cell
RAB40C ↑ RAB40C, member of RAS
oncogene family
GTPase activity Cell communication, signal
transduction
Platelets, liver, heart, kidney,
plasma
TNFAIP3 ↓ Tumor necrosis factor,
alpha-induced protein 3
(A20, Zin finger protein A20)
Transcription
regulator activity
Regulation of nucleobase,
nucleoside, nucleotide and
nucleic acid metabolism
Macrophages
↓, IS-free gene expression downregulated in tolerant patients compared to patients on IS; ↑, IS-free gene expression upregulated in
tolerant patients compared to patients on IS.
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IoT and the IS-IE signatures are shown in Table S8
and are discussed in Data S1.
Discussion
A number of studies, including our own, have suggested
gene expression signatures of tolerance in kidney transplan-
tation (7–9,11,32) or have described differential expression
of smaller gene sets (11,33,34). None had assessed the
confounding effect of IS. Baron et al (10) recently completed
a comprehensive review of all public data and concluded
that the expression of a set of 20 genes—mostly expressed
by B cells—may be used as a standardized tool for personal-
ized medicine in KTRs. Four genes from our IoT signature
(TCL1A, MS4A1, FCRL2, and CD79B) were included in this
20-gene set, but we now demonstrate that their expression
is highly affected by azathioprine and prednisone. Similarly,
it has been shown, in an independent cohort, that azathio-
prine affects the three-gene signature proposed by the
Immune Tolerance Network (35). We have shown in our
results, using the published signature of tolerance, that
Figure 5: The estimated probability of tolerance, based on the new nine-gene algorithm, is independent of immunosuppres-
sive (IS) drugs (gene expression measured in Fluidigm platform in patients from the GAMBIT study, cohorts 2 and 3). (A)
Effect of antiproliferative drug intake on estimated probability of tolerance in stable patients (n = 173) (No-MMF/Aza n = 33, Aza
n = 58, MMF n = 82). (B) Effect of CNI drug intake on estimated probability of tolerance in stable patients (n = 173) (No-Cyc/Tac
n = 38, Cyc n = 85, Tac n = 50). (C) Effect of prednisone intake on estimated probability of tolerance in stable patients off azathioprine
(n = 119); (n = 115) (Pred n = 52, No-Pred n = 63). (D) Comparison of estimated probability of tolerance, in paired samples prewith-
drawal and 3 to 6 months postwithdrawal completion from patients who have undergone clinically driven steroid withdrawal (n = 16,
none receiving azathioprine). The p-values for each statistical comparison were derived after adjustment in a linear regression model
for all other drugs/drug groups. The p-values for CNI drugs and for antiproliferative drugs were adjusted for multiple comparisons with
Bonferroni correction. The p-values for comparisons pre– and post–steroid withdrawal were derived from a Wilcoxon matched pairs
test. Cyc, ciclosporin; Tac, tacrolimus; Pred, prednisone/prednisolone; Aza, azathioprine; IS, immunosuppression; IoT, Indices of Toler-
ance study; GAMBIT, Genetic Analysis of Molecular Biomarkers of Immunological Tolerance; MMF, Mycophenolate Mofetil; CNI, Cal-
cineurin Inhibitors. Probability of tolerance cutoff was 0.54.
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KTRs who were maintained off steroids, on MMF and on
tacrolimus were being identified more frequently as possible
tolerant recipients.
Therefore, we asked, “Was this tolerance or response to
immunosuppressive therapy?” We have now demon-
strated that it is highly likely that it was the latter. Conse-
quently, we have developed and validated a new
noninvasive gene expression signature of tolerance that
is independent of IS drug effects and that additionally dif-
ferentiates tolerant patients from healthy controls. This
dictates that further analysis of tolerance signatures
using the correction proposed herein (or a similar
method) needs to be considered.
Additionally, we have demonstrated that the percent-
ages of transitional B cells in peripheral blood, which
had been described as characteristic of tolerant recipients,
were also significantly affected by IS drugs. We have not
addressed the specific mechanism by which each
immunosuppressant affects the intracellular pathways
in individual lymphocyte subsets, as this would
require longer-term studies and is beyond the scope of the
current one. However, commonly used immunosuppres-
sants, such as CNIs, which are fundamentally aimed at
inhibiting T cell activation and have only an indirect effect
on B cell activation, consistently showed little effect on
gene expression, the percentage of transitional B cell sub-
set size or the estimated probability of tolerance in our
study after adjustment for intake of other IS drugs. When
specifically addressed, transitional B cells exhibit the
capacity to decrease anti-inflammatory responses and pro-
duce anti-inflammatory cytokines (21,36). Therefore, we
do not question the important functionality that transitional
B cells may play in transplantation tolerance, but we
believe that the evidence of the role of B cells in tolerance
needs further scrutiny, particularly regarding the immuno-
suppression effects.
While there is no clear major genetic pathway connecting
the genes included in the new IS-independent signature,
literature reports suggest that at least some of these
genes have a mechanistic relevance to tolerance. For
example, a polymorphism in the NFjBIA gene resulting in
upregulation has been associated with higher rates of
acute liver transplant rejection (37), and BCL2A1 has been
shown to be a transcriptional target for NFjB (38). In our
study, both genes were downregulated in tolerant
patients. IGLC1 has been included in the expansion of the
B cell signature of tolerance in KTRs (39). Upregulation of
MS4A4A and RAB40C (upregulated in tolerant patients in
our study) has been associated with macrophage activa-
tion (40,41). TNFAIP3 (A20) is an NFjB regulatory protein
and its expression has been associated with outcome pre-
diction in kidney transplantation (42), but the regulation of
its expression and function in inflammatory responses has
been shown to be complex (43,44). The association found
herein of the downregulation of this gene with operational
tolerance merits further investigation.
External validation of the presented signature in other
independent cohorts would strengthen the confidence in
the generalizability of the results and would allow final
calibration before translation into clinical practice. Such
studies would require the collection of detailed clinical
phenotype data in parallel to the gene expression data
Figure 6: Comparison of gene expression signatures between tolerant recipients and healthy controls in patients from the
GAMBIT study (cohort 2). (A) Estimated probability of tolerance based on the 10-gene algorithm from IoT (gene expression mea-
sured by RT-qPCR, cutoff of 0.62). (B) Percentage of CD24hiCD38hi (transitional B cells) within the live CD20 + CD19 + B lympho-
cytes and CD27-IgD+IgM+ gate in peripheral blood. (C) Estimated probability of tolerance based on the new nine-gene algorithm (gene
expression measured in Fluidigm platform, cutoff of 0.54). Tolerant recipients (n = 14 for A and B, n = 13 for C); healthy controls
(n = 12 for A and B, n = 11 for C). The p-values were derived from a Wilcoxon test for comparison of independent samples. GAMBIT,
Genetic Analysis of Molecular Biomarkers of Immunological Tolerance; RT-qPCR, reverse transcription quantitative real-time polymer-
ase chain reaction; IoT, Indices of Tolerance.
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(best approached in a prospective manner). We are part
of two European consortia that will provide data for this
further validation (15,45,46).
In conclusion, this study emphasizes the importance of
assessing and correcting for the effect of diverse IS regi-
mens on gene expression–based biomarker signatures.
Using this correction, we identify a novel—and, arguably,
a more clinically robust—signature of operational toler-
ance, which we have validated in independent and exten-
sive cohorts of KTRs. Moreover, in our prospective
validation cohort, the estimated probability of tolerance
remained unchanged after steroid withdrawal, supporting
the view that the new signature highlights natural coun-
ter-regulatory mechanisms and excludes transient alter-
ations of the immune effector pathways by IS drugs.
Further evidence that our approach is uncovering toler-
ance-related responses is the fact that the estimated
probability of tolerance in tolerant patients is higher than
that of healthy controls, in agreement with studies
demonstrating the involvement of an active immune
response in tolerance (47).
We are aware that these results do bring into question
previous published evidence, and we have demonstrated
the effect of IS drugs on our own published signature.
Transplant physicians will require confidence in any novel
clinical-grade biomarker set of kidney transplantation tol-
erance, such as the new one described in this article,
prior to embarking on clinical trials of IS weaning or mini-
mization. Such trials are critical if we aim to reduce can-
cer risk and increase long-term survival with improved
quality of life for KTRs. In the current climate of stratified
medicine, these findings may also be relevant to autoim-
mune diseases and other disorders in which IS is a
prevalent drug therapy.
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